Table of Contents Author Guidelines Submit a Manuscript
International Journal of Nephrology
Volume 2012 (2012), Article ID 469265, 6 pages
http://dx.doi.org/10.1155/2012/469265
Review Article

Chronic Kidney Disease in Disadvantaged Populations

1Clinical and Translational Research Center, College of Medicine, Charles R. Drew University of Medicine and Science, 1731 East 120th Street, Los Angeles, California 90059, USA
2Office of Minority Health Research Coordination, NIDDK, National Institutes of Health, Building 2DEM, Room 902, 6707 Democracy Blvd., Bethesda, Maryland 20892, USA
3Division of Nephrology, Department of Medicine, Charles R. Drew University of Medicine and Science, Clinical Research Center Annex, 11705 Deputy Yamamoto Place, Los Angeles, California 90262, USA

Received 8 October 2011; Revised 10 January 2012; Accepted 25 January 2012

Academic Editor: Rudolph A. Rodriguez

Copyright © 2012 David Martins et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Coresh, E. Selvin, L. A. Stevens et al., “Prevalence of chronic kidney disease in the United States,” Journal of the American Medical Association, vol. 298, no. 17, pp. 2038–2047, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. J. Chen, R. P. Wildman, D. Gu et al., “Prevalence of decreased kidney function in Chinese adults aged 35 to 74 years,” Kidney International, vol. 68, no. 6, pp. 2837–2845, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. S. J. Chadban, E. M. Briganti, P. G. Kerr et al., “Prevalence of kidney damage in Australian adults: The AusDiab kidney study,” Journal of the American Society of Nephrology, vol. 14, no. 2, pp. S131–S138, 2003. View at Google Scholar · View at Scopus
  4. O. Viktorsdottir, R. Palsson, M. B. Andresdottir, T. Aspelund, V. Gudnason, and O. S. Indridason, “Prevalence of chronic kidney disease based on estimated glomerular filtration rate and proteinuria in Icelandic adults,” Nephrology Dialysis Transplantation, vol. 20, no. 9, pp. 1799–1807, 2005. View at Publisher · View at Google Scholar · View at Scopus
  5. A. Otero, P. Gayoso, F. Garcia, and A. L. de Francisco, “Epidemiology of chronic renal disease in the Galician population: results of the pilot Spanish EPIRCE study,” Kidney international. Supplement., no. 99, pp. S16–S19, 2005. View at Google Scholar · View at Scopus
  6. M. Cirillo, M. Laurenzi, M. Mancini, A. Zanchetti, C. Lombardi, and N. G. De Santo, “Low glomerular filtration in the population: prevalence, associated disorders, and awareness,” Kidney International, vol. 70, no. 4, pp. 800–806, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. A. S. Levey, J. Coresh, K. Bolton et al., “K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification,” American Journal of Kidney Diseases, vol. 39, no. 2, supplement 1, pp. S1–S266, 2002. View at Google Scholar
  8. S. I. Hallan, J. Coresh, B. C. Astor et al., “International comparison of the relationship of chronic kidney disease prevalence and ESRD risk,” Journal of the American Society of Nephrology, vol. 17, no. 8, pp. 2275–2284, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. S. Wild, G. Roglic, A. Green, R. Sicree, and H. King, “Global prevalence of diabetes: estimates for the year 2000 and projections for 2030,” Diabetes Care, vol. 27, no. 5, pp. 1047–1053, 2004. View at Publisher · View at Google Scholar · View at Scopus
  10. R. Correa-Rotter and L. González-Michaca, “Early detection and prevention of diabetic nephropathy: a challenge calling for mandatory action for Mexico and the developing world,” Kidney International, Supplement, vol. 68, no. 98, pp. S69–S75, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. A. M. Cusumano, G. G. Garcia, C. Di Gioia, O. Hermida, and C. Lavorato, “The Latin American dialysis and transplantation registry (RLDT) annual report 2004,” Ethnicity and Disease, vol. 16, no. S2, pp. 10–13, 2006. View at Google Scholar · View at Scopus
  12. F. A. M. Shaheen and A. A. Al-Khader, “Preventive strategies of renal failure in the Arab world,” Kidney International, Supplement, vol. 68, no. 98, pp. S37–S40, 2005. View at Publisher · View at Google Scholar · View at Scopus
  13. A. S. Go, G. M. Chertow, D. Fan, C. E. McCulloch, and C. Y. Hsu, “Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization,” New England Journal of Medicine, vol. 351, no. 13, pp. 1296–1370, 2004. View at Publisher · View at Google Scholar · View at Scopus
  14. “United States Renal Data System (USRDS) 2000 Annual Data”.
  15. R. S. Barsoum, “End-stage renal disease in North Africa,” Kidney International, Supplement, vol. 63, no. 83, pp. S111–S114, 2003. View at Google Scholar · View at Scopus
  16. V. Kher, N. E. Madias, J. T. Harrington et al., “End-stage renal disease in developing countries,” Kidney International, vol. 62, no. 1, pp. 350–362, 2002. View at Publisher · View at Google Scholar · View at Scopus
  17. US Renal Data System, USRDS 2010 annual data report: atlas of end-stage renal disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Disease, Bethesda, Md, USA, 2010.
  18. K. C. Norris and L. Y. Agodoa, “Unraveling the racial disparities associated with kidney disease,” Kidney International, vol. 68, no. 3, pp. 914–924, 2005. View at Publisher · View at Google Scholar · View at Scopus
  19. W. Rosamond, K. Flegal, K. Furie et al., “Heart disease and stroke statistics-2008 Update: a report from the American heart association statistics committee and stroke statistics subcommittee,” Circulation, vol. 117, no. 4, pp. e25–e46, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. R. Turner, R. Holman, I. Stratton et al., “Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38,” British Medical Journal, vol. 317, no. 7160, pp. 703–713, 1998. View at Google Scholar
  21. B. M. Egan, Y. Zhao, and R. N. Axon, “US trends in prevalence, awareness, treatment, and control of hypertension, 1988–2008,” Journal of the American Medical Association, vol. 303, no. 20, pp. 2043–2050, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. F. A. McAlister, K. Wilkins, M. Joffres et al., “Changes in the rates of awareness, treatment and control of hypertension in Canada over the past two decades,” CMAJ, vol. 183, no. 9, pp. 1007–1013, 2011. View at Publisher · View at Google Scholar
  23. W. H. L. Kao, M. J. Klag, L. A. Meoni et al., “MYH9 is associated with nondiabetic end-stage renal disease in African Americans,” Nature Genetics, vol. 40, no. 10, pp. 1185–1192, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. G. Genovese, D. J. Friedman, M. D. Ross et al., “Association of trypanolytic ApoL1 variants with kidney disease in African Americans,” Science, vol. 329, no. 5993, pp. 841–845, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. B. I. Freedman, J. B. Kopp, C. D. Langefeld et al., “The Apolipoprotein L1 (APOL1) gene and nondiabetic nephropathy in African Americans,” Journal of the American Society of Nephrology, vol. 21, no. 9, pp. 1422–1426, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. B. J. Materson, D. J. Reda, W. C. Cushman et al., “Single-drug therapy for hypertension in men—a comparison of six antihypertensive agents with placebo,” New England Journal of Medicine, vol. 328, no. 13, pp. 914–921, 1993, Erratum in: New England Journal of Medicine, vol. 330, no. 23, p. 1689, 1994. View at Publisher · View at Google Scholar
  27. K. C. Norris, N. Tareen, D. Martins, and N. D. Vaziri, “Implications of ethnicity for the treatment of hypertensive kidney disease, with an emphasis on African Americans,” Nature Clinical Practice Nephrology, vol. 4, no. 10, pp. 538–549, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. P. E. de Jong, M. van der Velde, R. T. Gansevoort, and C. Zoccali, “Screening for chronic kidney disease: where does Europe go?” Clinical Journal of the American Society of Nephrology, vol. 3, no. 2, pp. 616–623, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. E. L. Knight, H. M. Kramer, and G. C. Curhan, “High-normal blood pressure and microalbuminuria,” American Journal of Kidney Diseases, vol. 41, no. 3, pp. 588–595, 2003. View at Publisher · View at Google Scholar · View at Scopus
  30. K. C. Norris and L. Y. Agodoa, “Unraveling the racial disparities associated with kidney disease,” Kidney International, vol. 68, no. 3, pp. 914–924, 2005. View at Publisher · View at Google Scholar · View at Scopus
  31. A. V. Chobanian, G. L. Bakris, H. R. Black et al., “The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report,” Journal of the American Medical Association, vol. 289, no. 19, pp. 2560–2572, 2003. View at Publisher · View at Google Scholar · View at Scopus
  32. C. Baigent, K. Burbury, and D. Wheeler, “Premature cardiovascular disease in chronic renal failure,” Lancet, vol. 356, no. 9224, pp. 147–152, 2000. View at Google Scholar · View at Scopus
  33. F. C. Luft, C. E. Grim, N. Fineberg, and M. C. Weinberger, “Effects of volume expansion and contraction in normotensive whites, blacks, and subjects of different ages,” Circulation, vol. 59, no. 4, pp. 643–650, 1979. View at Google Scholar · View at Scopus
  34. G. Chandramohan, Y. Bai, K. Norris, B. Rodriguez-Iturbe, and N. D. Vaziri, “Effects of dietary salt on intrarenal angiotensin system, NAD(P)H oxidase, COX-2, MCP-1 and PAI-1 expressions and NF-κB activity in salt-sensitive and -resistant rat kidneys,” American Journal of Nephrology, vol. 28, no. 1, pp. 158–167, 2007. View at Publisher · View at Google Scholar · View at Scopus
  35. H. Hayakawa, K. Coffee, and L. Raij, “Endothelial dysfunction and cardiorenal injury in experimental salt-sensitive hypertension: effects of antihypertensive therapy,” Circulation, vol. 96, no. 7, pp. 2407–2413, 1997. View at Google Scholar · View at Scopus
  36. J. T. Wright Jr., G. Bakris, T. Greene et al., “Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial,” Journal of the American Medical Association, vol. 288, no. 19, pp. 2421–2431, 2002, Erratum in: Journal of the American Medical Association, vol. 295, no. 23, p. 2726, 2006. View at Publisher · View at Google Scholar
  37. L. J. Appel, J. T. Wright Jr., T. Greene et al., “Intensive blood-pressure control in hypertensive chronic kidney disease,” New England Journal of Medicine, vol. 363, no. 10, pp. 918–929, 2010. View at Publisher · View at Google Scholar
  38. “K/DOQI Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in Chronic Kidney Disease. Executive summary,” American Journal of Kidney Diseases, vol. 42, supplement 1, pp. 16–33, 2004.
  39. J. Lea, T. Greene, L. Hebert et al., “The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension,” Archives of Internal Medicine, vol. 165, no. 8, pp. 947–953, 2005. View at Publisher · View at Google Scholar · View at Scopus